Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name SMARCA4 mutant
Gene Variant Detail

SMARCA4 mutant (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04204941 Phase III Doxorubicin Doxorubicin + Tazemetostat Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma Recruiting USA | GBR | CAN 1
NCT05639751 Phase I Docetaxel + PRT3789 PRT3789 PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation Recruiting USA | NLD | FRA | ESP 1
NCT03297606 Phase II Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (CAPTUR) Recruiting CAN 0
NCT05286801 Phase Ib/II Atezolizumab + Tiragolumab Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors Recruiting USA | CAN | AUS 0
NCT02114229 Phase II Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) Active, not recruiting USA 0
NCT04611139 Phase I Pembrolizumab + Seclidemstat Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers Withdrawn USA 0
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT05861050 Phase Ib/II Glofitamab-gxbm + Lenalidomide + Obinutuzumab + Venetoclax Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma Recruiting USA 0
NCT05407441 Phase Ib/II Ipilimumab + Nivolumab + Tazemetostat Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors Recruiting USA 0
NCT05687136 Phase I M1774 + Peposertib Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors Recruiting USA 0
NCT02601950 Phase II Tazemetostat A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma Completed USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS 1
NCT06560645 Phase I PRT7732 A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation Recruiting USA | AUS 0
NCT06561685 Phase I LY4050784 A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting USA 1
NCT05495464 Phase I Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma Recruiting USA 0
NCT02601937 Phase I Tazemetostat A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma Completed USA | NLD | ITA | GBR | FRA | DNK | DEU | CAN | AUS 0